Navigation Links
Victory Pharma, Inc. Announces FDA Accepts MGX006 NDA for Review

SAN DIEGO, July 13 /PRNewswire/ -- Victory Pharma, Inc. ("Victory") announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Victory's lead investigational rug, MGX006. If approved, MGX006 will provide patients and healthcare providers the advantage of a proven antiemetic agent combined with a proprietary formulation ideally suited for the treatment of nausea and vomiting.

"Acceptance of the MGX006 NDA is a significant milestone, it demonstrates Victory's ability to grow its commercial portfolio via internal product development in addition to in-licensing products," said Matt Heck, Chief Executive Officer of Victory. "Pending FDA approval, we are planning for a first half of 2010 product launch, allowing Victory to further leverage its 150 person field sales organization. Given many patients suffering from pain also suffer from emesis, there is a good fit between MGX006 and Victory's growing, pain management franchise."

Approximately 25 million prescriptions are written annually in the U.S. for anti-emetic therapeutics. The vast majority of these prescriptions are for traditional, oral solid drug formulations, which can be problematic among patients with emesis.

"We believe the attributes of MGX006 will provide an important alternative for patients suffering from nausea and vomiting of various etiologies," said Dr. Shawn Scranton, Vice President, Scientific Operations. "We look forward to working closely with the FDA on a timely approval."

About Victory Pharma

Founded in 2003, Victory Pharma, Inc. is a privately held specialty pharmaceutical company headquartered in San Diego, CA focused on acquiring, developing, and marketing products to treat pain and related conditions. Victory markets its lead product, NAPRELAN(R) (naproxen sodium) Controlled-Release Tablets and other pain products to pain management specialists, rheumatologists, orthopedic surgeons, and selected primary care physicians through its physician office-based field sales force. Victory is also developing proprietary products for the treatment of chronic pain and common opiate- induced side effects Further information regarding Victory Pharma is available at

NAPRELAN(R) is a trademark of Elan Corporation, plc.

SOURCE Victory Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. President Obama Delivers Historic Victory for Americas Kids and Health over Tobacco
2. American College of Chest Physicians Celebrates the Nations Victory for Tobacco Control
3. Mississippi Tobacco Tax Increase is a Victory for Kids and Taxpayers
4. Victory! Colombian Government Cuts Price of Abbotts Lifesaving AIDS Drug Kaletra 55%, Says AHF
5. Hawaii Cigarette Tax Increase Delivers Victory for Kids and Taxpayers
6. Rhode Island Cigarette Tax Increase Delivers Victory for Kids and Taxpayers; $1 Increase Gives State Highest Cigarette Tax in the Nation
7. LYSOL NASCAR Sponsorship - A Victory for Fans Pit Stops
8. Consumers Win Major Victory Over Seafood Scaremongers
9. Executive Order on Embryonic Stem Cells A Sad Victory of Politics Over Science and Ethics, Says Cardinal Rigali
10. Victory Pharma Announces $45 Million Equity Financing
11. Supreme Court Ruling is a Victory for Consumers Injured by Dangerous Drugs, Says Hissey Kientz, LLP
Post Your Comments:
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology: